Ask about this productRelated genes to: GINS2 antibody
- Gene:
- GINS2 NIH gene
- Name:
- GINS complex subunit 2
- Previous symbol:
- -
- Synonyms:
- PSF2, Pfs2
- Chromosome:
- 16q24.1
- Locus Type:
- gene with protein product
- Date approved:
- 2006-05-04
- Date modifiied:
- 2016-03-21
Related products to: GINS2 antibody
Related articles to: GINS2 antibody
- Lung adenocarcinoma (LUAD) is the most prevalent subtype of lung cancer, with lymph node metastasis serving as a key prognostic factor. MUC5B, a member of the mucin family, has been implicated in the progression of various cancers, yet its specific role in LUAD metastasis remains underexplored. This study aimed to investigate the role of MUC5B in LUAD progression and its potential as a biomarker for lymph node metastasis. - Source: PubMed
Publication date: 2025/12/02
Song WeijianYang QianDu MinjunWei JiacongZhou BoxuanShi JianweiLiang LinchuanLiu ZixuLiang MeiLi MianyangGao Yushun - The GINS complex subunit 2 (GINS2) is crucial for DNA replication, but its specific roles in oral squamous cell carcinoma (OSCC) pathogenesis and tumor microenvironment (TME) modulation are poorly defined. - Source: PubMed
Publication date: 2025/11/05
Wei BoYin JiajiaShi ChuyanSun HuiLiu BingChen Peng - Cervical cancer (CC) is the fourth most frequently diagnosed cancer and the fourth leading cause of cancer-related deaths in women worldwide, however, the treatment options for advanced CC are limited. Therefore, there is an urgent need in the clinic for reliable prognostic models to guide clinical decision-making. - Source: PubMed
Publication date: 2025/09/04
Zou DaoyangWu XiuhongXin XiXu Tianwen - Neuroblastoma (NB) is a heterogeneous pediatric malignancy with highly variable outcomes. Traditional clinical factors, such as stage, MYCN status, and patient age, often fail to fully capture disease complexity. Recent advances in single-cell sequencing and integrative transcriptomic analyses provide an opportunity to identify more precise prognostic biomarkers and guide individualized therapies. This study aimed to develop and validate a robust prognostic model for NB by integrating single-cell and bulk transcriptomic data. - Source: PubMed
Publication date: 2025/07/04
Wu ZhanboSun NingningDong YinanZhang LiSun JifengLi XinLi Runmei - Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with a 5-year overall survival (OS) rate of approximately 12%. More than 90% of PDAC patients harbor oncogenic mutations in the Kirsten rat sarcoma viral homolog (KRAS) gene. MRTX1133 (MRTX), a novel inhibitor of KRAS (the most common KRAS mutation found in pancreatic and colon cancers) has shown promise as a therapeutic agent. To address reported resistance to MRTX, we adapted our anti-leukemia co-targeting strategy and evaluated a combination of MRTX and Bedaquiline (BED), an FDA-approved inhibitor of mitochondrial ATP production, in in vitro human PDAC models. The combination of MRTX and BED demonstrated enhanced cytotoxic effects by disrupting all 11 genes within the DNA helicase family (CMG complex: CDC45-MCM-GINS), which are essential for initiating DNA replication and regulating cell cycle progression. Notably, real-world data analysis from Caris Life Sciences and NCI-TCGA database revealed that low transcriptomic expression of the DNA helicase CMG complex was significantly associated with prolonged survival (e.g., low CDC45 expression and low GINS2 expression with greater than 8 months longer overall survival) in PDAC patients with KRAS mutations (N = 9,717; P < 0.00001). However, this combination therapy also triggered strong pro-survival nuclear reprogramming. This effect was mediated by significant genetic activation of an NFκB2-DDIT (DNA damage-induced transcript) axis, which supported tumor chromosomal integrity and DNA repair mechanisms. To overcome NFκB2-driven resistance mechanisms, we explored a triple-targeting strategy that addresses metabolic and genomic plasticity in addition to actively intercepting cell division. This approach combines MRTX1133, Bedaquiline, and the NFκB2 inhibitor SN52, offering a novel therapeutic avenue to treat aggressive pancreatic cancer and potentially improve patient outcomes. - Source: PubMed
Publication date: 2025/05/26
Xiao JeffreyKim JoshuaPark BrandonBaylink David JKwon CedricTran VictoriaLee ScottCodorniz KevinTan LarenMoreno Pamela LoboSchill-Depew AmyMirshahidi SaiedDe Semir DavidHanna DianaNaqvi KiranCao HuynhChen Chien-ShingXiu JoanneLenz Heinz-JosefMirshahidi HamidReeves Mark EXu Yi